レムデシビル投与で死亡率6割減、米製薬会社公表

Death rate reduced by 60% after administration of lemdecivir, announced by US pharmaceutical company

Death rate reduced by 60% after administration of lemdecivir, announced by US pharmaceutical company
アメリカの製薬会社ギリアド・サイエンシズは10日、重症患者で「レムデシビル」を投与された312人と通常の治療を受けた818人を対象に行った実験の比較データを公表

American pharmaceutical company Gilead Sciences published on October 10 comparative data of an experiment conducted on 312 severely ill patients who received “lemdecivir” and 818 patients who received regular treatment.

American pharmaceutical company Gilead Sciences published on October 10 comparative data of an experiment conducted on 312 severely ill patients who received “lemdecivir” and 818 patients who received regular treatment.
「レムデシビル」を投与された患者のうち、14日以内に回復したのは74.7%だったのに対して、通常の治療を受けた患者では59.9%にとどまったということです

Of the patients who received lemdecivir

Of the patients who received lemdecivir
また、「レムデシビル」を投与された患者は、通常の治療を受けた患者と比べて、死亡率が62%下がったことも明らかにしています

Also, it has been clarified that the mortality rate of patients who received “lemdecivir” was 62% lower than that of patients who received usual treatment.

Also, it has been clarified that the mortality rate of patients who received “lemdecivir” was 62% lower than that of patients who received usual treatment.
ギリアド・サイエンシズ社は、「これは重要な発見で、さらなる治験による裏付けが必要だ」としています

Gilead Sciences says, This is an important discovery and needs further clinical trial support.

Gilead Sciences says, This is an important discovery and needs further clinical trial support.